Prospects: Histone deacetylase inhibitors

Journal of Cellular Biochemistry

Volumn 96, Issue 2, 2005, Pages 293-304

  Dokmanovic, Milos ^a   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Thioredoxin; Thioredoxin binding protein; Transcription factor complex

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ALIPHATIC CARBOXYLIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BORTEZOMIB; CYCLOPEPTIDE; DEPSIPEPTIDE; FLAVOPIRIDOL; FLUDARABINE; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; LBH 589A; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NATURAL PRODUCT; OXAMFLATIN; PROTEASOME INHIBITOR; SK 7041; SK 7046; THIOREDOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL TRANSFORMATION; CHROMATIN STRUCTURE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DEACETYLATION; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; GENE EXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; MOUSE; MYELOMA CELL; NONHUMAN; OXIDATION REDUCTION REACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; T CELL LYMPHOMA; TUMOR MODEL;

ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; OXIDATION-REDUCTION;

EID: 26444439216     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20532     Document Type: Article

References (51)

1. Allfrey VG, Faulkner R, Mirsky AE. 1964. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 51:786-794.
2. Arner ES, Holmgren A. 2000. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102-6109.
3. Blander G, Guarente L. 2004. The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435.
4. Butler LM, Zhou X, Xu W-S, Scher HI, Rifkind RA, Marks PA, Richon VM. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci 99:11700-11705.
5. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY. 2001. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92:1300-1304.
6. Curtin M, Glaser K. 2003. Histone deacetylase inhibitors: The Abbott experience. Curr Med Chem 10:2373-2392.
7. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. 2002. Histone deacetylases: Characterization of the classical HDAC family. Biochem J 370(Pt):737-749.
8. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. 2004. Acetylation of proteins as novel target for antitumor therapy: Review article. Amino Acids 26:435-441.
9. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. 2005. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528.
10. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193.
11. Fischle W, Wang Y, Allis CD. 2003. Binary switches and modification cassettes in histone biology and beyond. Nature 425:475-479.
12. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. 2003. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310:529-536.
13. Gray SG, Qian CN, Furge K, Guo X, Teh BT. 2004. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24:773-795.
14. Gregoretti IV, Lee YM, Goodson HV. 2004. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 338:17-31.
15. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101:1241-1246.
16. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. 2003. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389-43894.
17. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. 2004. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177-189.
18. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720-728.
19. Johnstone RW, Licht JD. 2003. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4:13-18.
20. Jose B, Oniki Y, Kato T, Nishino N, Sumida Y, Yoshida M. 2004. Novel histone deacetylase inhibitors: Cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg Med Chem Lett 14:5343-5346.
21. Kelly WK, Marks AP. 2005. Drug insight: Histone deacetylase inhibitors development of the new targeted anticancer agent suberolyanilide hydroxamic acid. Nat Clinc Prac 2:1-8.
22. Kelly WK, O'Connor OA, Krug L, Chiao J, Heaney M, Curley T, MacGregor-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, olgac S, Marks P, Scher H, Richon VM. 2005. Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol 23:3923-3931.
23. Lehrmann H, Pritchard LL, Harel-Bellan A. 2002. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41-65.
24. Lindemann RK, Gabrielli B, Johnstone RW. 2004. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788.
25. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251-260.
26. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. 2001. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202.
27. Marks PA, Richon VM, Miller T, Kelly WK. 2004. Histone deacetylase inhibitors. Adv Cancer Res 91:137-168.
28. Miller TA, Witter DJ, Belvedere S. 2003. Histone deacetylase inhibitors. J Med Chem 46:5097-5116.
29. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101:540-545.
30. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. 2004. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112:26-32.
31. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Bang YJ. 2004. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10:5271-5281.
32. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:3697-3702.
33. Pei XY, Dai Y, Grant S. 2004. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839-3852.
34. Piekarz R, Bates S. 2004. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289-2298.
35. Piekarz R, Frye RA, Turner ML, Wright J, Leonard J, Allen S, Bates S. 2004a. Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Proc Am Soc Clin Onc 22: Abstract 2.
36. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE. 2004b. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103:4636-4643.
37. Rascle A, Johnston JA, Amati B. 2003. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 23:4162-4173.
38. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. 1996. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93:5705-5708.
39. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007.
40. Rosato RR, Grant S. 2003. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37.
41. Rosato RR, Grant S. 2004. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13:21-38.
42. Sengupta N, Seto E. 2004. Regulation of histone deacetylase activities. J Cell Biochem 93:57-67.
43. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. 2004. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 12:1325-1334.
44. Spotswood HT, Turner BM. 2002. An increasingly complex code. J Clin Invest 110:577-582.
45. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678.
46. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. 2004. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566.
47. Verdin E, Dequiedt F, Kasler HG. 2003. Class II histone deacetylases: Versatile regulators. Trends Genet 19:286-293.
48. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, Gabrielli B. 2003. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. Faseb J 17:1550-1552.
49. Yoshida C, Melo JV. 2004. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 79:420-433.
50. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. 2003. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351-2358.
51. Zhang Y, Reinberg D. 2001. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343-2360.